Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
What's the Difference: Biologics vs Biosimilars in Cancer Care
A near miss incident involving a nurse mistakenly queuing filgrastim instead of pegfilgrastim highlights the challenges in community practice settings with biosimilar usage. Biosimilars, defined by the FDA as highly similar but not identical to reference biologics, have become essential in cancer care due to their lower costs and accelerated FDA approval. Nurses play a crucial role in their administration, verification, and patient education, ensuring the right medication is given to the right patient.
Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer
Tecentriq plus neoadjuvant chemotherapy followed by adjuvant Tecentriq did not significantly improve event-free survival in triple-negative breast cancer patients, missing the primary end point. While no overall survival benefit was observed, Tecentriq boosted the pathological complete response rate. Safety analysis showed similar rates of treatment-emergent side effects between groups.
Polyethylene glycols trigger Ca2+ signals, activate cytokines production
Polyethylene glycol (PEG) is crucial in medical applications, enhancing drug bioavailability and reducing immunogenicity. However, PEGylated nanopharmaceuticals have caused side effects, particularly after intravenous administration. PEG's mechanism of side effects is unclear but may involve immune response stimulation. Studies show PEG can induce cytokine production and neutrophil extracellular trap formation, potentially through Ca²⁺ signaling, highlighting the need for further research on PEG's immunological effects.
Race Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Race Oncology Ltd submitted an ethics and regulatory package for a Phase 1 trial of RC220 bisantrene at Southside Cancer Care Centre, with first patient recruitment anticipated in Q1 2025. The trial aims to assess RC220's safety and tolerability in combination with doxorubicin, with potential to reduce side effects and improve outcomes. Additional sites in Australia, Hong Kong, and South Korea are planned, aiming for 10 active sites. The trial will use a Bayesian statistical design and proceed in two stages, with Stage 2 planned to begin upon HREC approval.
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type
New TNBC treatment at Roswell Park achieves 66% complete remission without immune-related adverse events, using a combination of chemotherapy and immunotherapy.
Eight nanotechnology companies to watch out for
Nanotechnology in medicine includes drug discovery, tissue engineering, imaging, and diagnostics. Notable nano-drugs include Doxil, Abraxane, Myocet, and Hensify. Key companies: Sona Nanotech (non-toxic gold nanorods for photothermal therapy), Nanobiotix (NBTXR3 radioenhancer), Cour Pharmaceuticals (immune-mediated disease treatment), ARIZ Precision Medicine (targeted cancer drug delivery), Blueberry Therapeutics (fungal nail infection treatment), Cello Therapeutics (biomimetic nanoparticles for immunotherapy), Nanoform (API nanoparticles via CESS technology), Zylo Therapeutics (Z-pods for enhanced bioavailability). Market size expected to grow to $13.9 billion by 2033.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
Nivolumab (Opdivo) plus standard chemotherapy (AVD) showed longer progression-free survival (PFS) and better side-effect profile compared to brentuximab vedotin (Adcetris) plus AVD in advanced-stage Hodgkin's lymphoma patients, according to the SWOG S1826 trial.
New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
A new combo drug therapy, N-AVD, halves death risk from advanced Hodgkin lymphoma, with fewer side effects than the previous BV-AVD regimen, according to a study published in the New England Journal of Medicine.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath